retatrutide news today recency 3 Today, we shared new data from two Phase trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Where to Get: Can

Dose-by-Dose Breakdown at Week 12 Understanding how different doses perform at the 3-month mark helps set appropriate expectations based on your specific protocol

Martn G

Protein First, Always Your body needs approximately 100-120g of protein daily to preserve muscle mass during weight loss

Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations

This helps in understanding the downstream effects on cellular proliferation, differentiation, and metabolism

For some patients: For others: The future role of Retatrutide will become clearer as longer-term data continues to emerge